411 related articles for article (PubMed ID: 16181302)
1. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Wani S; Sampliner RE; Weston AP; Mathur S; Hall M; Higbee A; Sharma P
Aliment Pharmacol Ther; 2005 Oct; 22(7):627-33. PubMed ID: 16181302
[TBL] [Abstract][Full Text] [Related]
2. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
3. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus.
Gerson LB; Shetler K; Triadafilopoulos G
Dig Liver Dis; 2005 Sep; 37(9):651-8. PubMed ID: 15919250
[TBL] [Abstract][Full Text] [Related]
4. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor.
Fass R; Sampliner RE; Malagon IB; Hayden CW; Camargo L; Wendel CS; Garewal HS
Aliment Pharmacol Ther; 2000 May; 14(5):597-602. PubMed ID: 10792123
[TBL] [Abstract][Full Text] [Related]
5. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
Ortiz A; Martínez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
[TBL] [Abstract][Full Text] [Related]
6. Maximal acid reflux control for Barrett's oesophagus: feasible and effective.
Srinivasan R; Katz PO; Ramakrishnan A; Katzka DA; Vela MF; Castell DO
Aliment Pharmacol Ther; 2001 Apr; 15(4):519-24. PubMed ID: 11284781
[TBL] [Abstract][Full Text] [Related]
7. Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy.
Frazzoni M; Savarino E; Manno M; Melotti G; Mirante VG; Mussetto A; Bertani H; Manta R; Conigliaro R
Aliment Pharmacol Ther; 2009 Sep; 30(5):508-15. PubMed ID: 19519732
[TBL] [Abstract][Full Text] [Related]
8. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
Todd JA; Basu KK; de Caestecker JS
Aliment Pharmacol Ther; 2005 Apr; 21(8):969-75. PubMed ID: 15813832
[TBL] [Abstract][Full Text] [Related]
9. Control of intra-oesophageal pH in patients with Barrett's oesophagus on omeprazole-sodium bicarbonate therapy.
Gerson LB; Mitra S; Bleker WF; Yeung P
Aliment Pharmacol Ther; 2012 Apr; 35(7):803-9. PubMed ID: 22356659
[TBL] [Abstract][Full Text] [Related]
10. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
Peters FT; Kuipers EJ; Ganesh S; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
Aliment Pharmacol Ther; 1999 Jul; 13(7):921-6. PubMed ID: 10383527
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year.
de Bortoli N; Martinucci I; Piaggi P; Maltinti S; Bianchi G; Ciancia E; Gambaccini D; Lenzi F; Costa F; Leonardi G; Ricchiuti A; Mumolo MG; Bellini M; Blandizzi C; Marchi S
Aliment Pharmacol Ther; 2011 May; 33(9):1019-27. PubMed ID: 21385192
[TBL] [Abstract][Full Text] [Related]
12. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy.
Basu KK; Bale R; West KP; de Caestecker JS
Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1187-92. PubMed ID: 12439112
[TBL] [Abstract][Full Text] [Related]
13. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
Sharma P; Sampliner RE; Camargo E
Am J Gastroenterol; 1997 Apr; 92(4):582-5. PubMed ID: 9128303
[TBL] [Abstract][Full Text] [Related]
14. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
Menges M; Müller M; Zeitz M
Am J Gastroenterol; 2001 Feb; 96(2):331-7. PubMed ID: 11232672
[TBL] [Abstract][Full Text] [Related]
15. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
Ouatu-Lascar R; Triadafilopoulos G
Am J Gastroenterol; 1998 May; 93(5):711-6. PubMed ID: 9625114
[TBL] [Abstract][Full Text] [Related]
16. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
17. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study.
Peters FT; Ganesh S; Kuipers EJ; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
Gut; 1999 Oct; 45(4):489-94. PubMed ID: 10486353
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2006 Sep; 38(9):643-8. PubMed ID: 16627016
[TBL] [Abstract][Full Text] [Related]
19. Acid suppression in the long-term treatment of peptic stricture and Barrett's oesophagus.
Lundell L
Digestion; 1992; 51 Suppl 1():49-58. PubMed ID: 1356869
[TBL] [Abstract][Full Text] [Related]
20. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus.
Marshall RE; Anggiansah A; Manifold DK; Owen WA; Owen WJ
Gut; 1998 Nov; 43(5):603-6. PubMed ID: 9824338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
